-
S.
Nilsson,
R.
Larsen,
S.
Fosså,
L.
Balteskard,
K.
Borch,
J.
Westlin,
G.
Salberg,
O.
Bruland
(2005)
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research, 11 12
-
T.
Wada,
T.
Nakashima,
Nishina
Hiroshi,
J.
Penninger
(2006)
RANKL-RANK signaling in osteoclastogenesis and bone disease.
Trends in molecular medicine, 12 1
-
C.
Ryan,
P.
Saylor,
J.
Everly,
O.
Sartor
(2014)
Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
The oncologist, 19 10
-
S.
Nilsson,
N.
Vogelzang,
A.
Sartor,
D.
Bottomley,
Robert
Coleman,
I.
Skjorestad,
Mona
Wahba,
C.
Parker
(2014)
1.5-Year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA Study 9.
Clinical advances in hematology & oncology : H&O, 12 4 Suppl 11
-
P.
Cheetham,
D.
Petrylak
(2012)
Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.
Oncology, 26 4
-
Matthew
Smith,
F.
Saad,
R.
Coleman,
N.
Shore,
K.
Fizazi,
B.
Tombal,
K.
Miller,
P.
Sieber,
L.
Karsh,
R.
Damião,
T.
Tammela,
B.
Egerdie,
H.
Poppel,
J.
Chin,
J.
Morote,
F.
Gómez‐Veiga,
T.
Borkowski,
Z.
Ye,
Amy
Kupic,
R.
Dansey,
C.
Goessl
(2012)
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
The Lancet, 379
-
Joelle
el-Amm,
Ashley
Freeman,
N.
Patel,
J.
Aragon-Ching
(2013)
Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
Prostate Cancer, 2013
-
Yu‐Chen
Lee,
Song-Chang
Lin,
Guoyu
Yu,
Chien-jui
Cheng,
B.
Liu,
Hsuan-Chen
Liu,
D.
Hawke,
N.
Parikh,
A.
Varkaris,
P.
Corn,
C.
Logothetis,
R.
Satcher,
L.
Yu-Lee,
G.
Gallick,
Sue-Hwa
Lin
(2015)
Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.
Cancer research, 75 22
-
I.
Tannock,
R.
Wit,
W.
Berry,
J.
Horti,
A.
Płużańska,
K.
Chi,
S.
Oudard,
C.
Théodore,
N.
James,
I.
Turesson,
M.
Rosenthal,
M.
Eisenberger
(2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
The New England journal of medicine, 351 15
-
Joelle
el-Amm,
J.
Aragon-Ching
(2013)
The changing landscape in the treatment of metastatic castration-resistant prostate cancer
Therapeutic Advances in Medical Oncology, 5
-
Matthew
Smith,
B.
Egerdie,
Narciso
Toriz,
R.
Feldman,
T.
Tammela,
F.
Saad,
J.
Heracek,
M.
Szwedowski,
C.
Ke,
Amy
Kupic,
B.
Leder,
C.
Goessl
(2009)
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
The New England journal of medicine, 361 8
-
W.
Dougall,
M.
Glaccum,
K.
Charrier,
Kathy
Rohrbach,
K.
Brasel,
T.
Smedt,
E.
Daro,
Jeffery
Smith,
Mark
Tometsko,
C.
Maliszewski,
A.
Armstrong,
Victor
Shen,
S.
Bain,
D.
Cosman,
Dirk
Anderson,
P.
Morrissey,
J.
Peschon,
J.
Schuh
(1999)
RANK is essential for osteoclast and lymph node development.
Genes & development, 13 18
-
A.
Armstrong,
E.
Garrett-Mayer,
Yi-Chun
Yang,
M.
Carducci,
I.
Tannock,
R.
Wit,
M.
Eisenberger
(2007)
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 25
-
M.
Morris,
C.
Higano,
H.
Scher,
Christopher
Sweeney,
E.
Antonarakis,
D.
Shevrin,
Charles
Ryan,
Y.
Loriot,
K.
Fizazi,
N.
Pandit-Taskar,
Jose
Garcia-Vargas,
K.
Lyseng,
M.
Bloma,
A.
Aksnes,
J.
Carrasquillo
(2014)
765PDSAFETY OF RADIUM-223 DICHLORIDE (RA) WITH DOCETAXEL (D) IN PATIENTS (PTS) WITH BONE METASTASES (METS) FROM CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A PHASE 1/2A CLINICAL TRIAL.
Annals of oncology : official journal of the European Society for Medical Oncology, 25 suppl_4
-
D.
Dearnaley,
M.
Mason,
M.
Parmar,
Karen
Sanders,
M.
Sydes
(2009)
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
The Lancet. Oncology, 10
-
A.
Armstrong,
E.
Garrett-Mayer,
Y.
Yang,
R.
Wit,
I.
Tannock,
M.
Eisenberger
(2007)
A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis
Clinical Cancer Research, 13
-
N.
Dubrawsky
(1989)
Cancer statistics
CA: A Cancer Journal for Clinicians, 39
-
M.
Oefelein,
V.
Ricchiuti,
W.
Conrad,
M.
Resnick
(2002)
Skeletal fractures negatively correlate with overall survival in men with prostate cancer.
The Journal of urology, 168 3
-
A.
Laing,
D.
Ackery,
R.
Bayly,
R.
Buchanan,
V.
Lewington,
A.
Mcewan,
P.
Macleod,
M.
Zivanovic
(1991)
Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.
The British journal of radiology, 64 765
-
J.
Body,
H.
Bone,
R.
Boer,
A.
Stopeck,
C.
Poznak,
R.
Damião,
K.
Fizazi,
D.
Henry,
T.
Ibrahim,
A.
Lipton,
F.
Saad,
N.
Shore,
T.
Takano,
A.
Shaywitz,
Huei
Wang,
O.
Bracco,
A.
Braun,
P.
Kostenuik
(2015)
Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
European journal of cancer, 51 13
-
David
Smith,
Matthew
Smith,
C.
Sweeney,
A.
Elfiky,
C.
Logothetis,
P.
Corn,
N.
Vogelzang,
E.
Small,
A.
Harzstark,
M.
Gordon,
U.
Vaishampayan,
N.
Haas,
A.
Spira,
P.
Lara,
Chia‐Chi
Lin,
S.
Srinivas,
A.
Sella,
P.
Schöffski,
C.
Scheffold,
A.
Weitzman,
M.
Hussain
(2013)
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 4
-
J
Turner,
P.
Claringbold,
E
Hetherington,
P.
Sorby,
A.
Martindale
(1989)
A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 7 12
-
R.
Siegel,
K.
Miller,
A.
Jemal
(2015)
Cancer statistics, 2015
CA: A Cancer Journal for Clinicians, 65
-
A.
Serafini,
S.
Houston,
I.
Resche,
D.
Quick,
F.
Grund,
P.
Ell,
A.
Bertrand,
F.
Ahmann,
E.
Orihuela,
R.
Reid,
R.
Lerski,
B.
Collier,
J.
Mckillop,
G.
Purnell,
A.
Pecking,
F.
Thomas,
K.
Harrison
(1998)
Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 4
-
O.
Sartor,
R.
Reid,
P.
Hoskin,
D.
Quick,
P.
Ell,
R.
Coleman,
J.
Kotler,
L.
Freeman,
P.
Olivier
(2004)
Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
Urology, 63 5
-
F.
Saad,
D.
Gleason,
R.
Murray,
S.
Tchekmedyian,
P.
Venner,
L.
Lacombe,
J.
Chin,
J.
Vinholes,
J.
Goas,
Bee
Chen
(2002)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Journal of the National Cancer Institute, 94 19
-
Clinical Medicine Insights: Oncology
-
O.
Sartor,
R.
Coleman,
S.
Nilsson,
D.
Heinrich,
S.
Helle,
J.
O’Sullivan,
S.
Fosså,
A.
Chodacki,
P.
Wiechno,
J.
Logue,
A.
Widmark,
Dag
Johannessen,
P.
Hoskin,
N.
James,
A.
Solberg,
I.
Syndikus,
N.
Vogelzang,
C.
O'Bryan-Tear,
M.
Shan,
Ø.
Bruland,
C.
Parker
(2014)
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
The Lancet. Oncology, 15 7
-
A.
Himelstein,
R.
Qin,
P.
Novotny,
D.
Seisler,
J.
Khatcheressian,
John
Roberts,
S.
Grubbs,
T.
O'Connor,
D.
Weckstein,
C.
Loprinzi,
C.
Shapiro
(2015)
CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.
Journal of Clinical Oncology, 33
-
G.
Henriksen,
D.
Fisher,
J.
Roeske,
Ø.
Bruland,
R.
Larsen
(2003)
Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 44 2
-
D.
Dearnaley,
M.
Sydes,
M.
Mason,
M.
Stott,
C.
Powell,
A.
Robinson,
P.
Thompson,
L.
Moffat,
S.
Naylor,
M.
Parmar
(2003)
A Double-Blind , Placebo-Controlled , Randomized Trial of Oral Sodium Clodronate for Metastatic Prostate Cancer ( MRC PR 05 Trial )
-
N.
Sathiakumar,
E.
Delzell,
M.
Morrisey,
C.
Falkson,
M.
Yong,
V.
Chia,
J.
Blackburn,
T.
Arora,
M.
Kilgore
(2011)
Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006
Prostate Cancer and Prostatic Diseases, 14
-
K.
Fizazi,
A.
Lipton,
X.
Mariette,
J.
Body,
Y.
Rahim,
J.
Gralow,
G.
Gao,
Ling
Wu,
W.
Sohn,
S.
Jun
(2009)
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 10
-
S.
Teitelbaum
(2000)
Bone resorption by osteoclasts.
Science, 289 5484
-
S.
Nilsson,
L.
Franzén,
C.
Parker,
C.
Tyrrell,
R.
Blom,
J.
Tennvall,
B.
Lennernäs,
U.
Petersson,
D.
Johannessen,
M.
Sokal,
K.
Pigott,
J.
Yachnin,
M.
Garkavij,
P.
Strang,
J.
Harmenberg,
B.
Bolstad,
O.
Bruland
(2007)
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
The Lancet. Oncology, 8 7
-
(1989)
Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer
-
J.
Carrasquillo,
J.
O’Donoghue,
N.
Pandit-Taskar,
J.
Humm,
D.
Rathkopf,
S.
Slovin,
M.
Williamson,
K.
Lacuna,
A.
Aksnes,
S.
Larson,
H.
Scher,
M.
Morris
(2013)
Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging, 40
-
M.
McDevitt,
G.
Sgouros,
R.
Finn,
J.
Humm,
J.
Jurcic,
S.
Larson,
D.
Scheinberg
(1998)
Radioimmunotherapy with alpha-emitting nuclides
European Journal of Nuclear Medicine, 25
-
J.
Goyal,
E.
Antonarakis
(2012)
Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.
Cancer letters, 323 2
-
S.
Nilsson,
L.
Franzén,
C.
Parker,
C.
Tyrrell,
R.
Blom,
J.
Tennvall,
B.
Lennernäs,
U.
Petersson,
D.
Johannessen,
M.
Sokal,
K.
Pigott,
C.
O'Bryan-Tear,
M.
Thuresson,
B.
Bolstad,
Ø.
Bruland
(2013)
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
Clinical genitourinary cancer, 11 1
-
W.
Mertens,
L.
Stitt,
A.
Porter
(1993)
Strontium 89 Therapy and Relief of Pain in Patients with Prostatic Carcinoma Metastatic to Bone: A Dose Response Relationship?
American Journal of Clinical Oncology, 16
-
O.
Sartor,
R.
Reid,
D.
Bushnell,
D.
Quick,
P.
Ell
(2007)
Safety and efficacy of repeat administration of samarium Sm‐153 lexidronam to patients with metastatic bone pain
Cancer, 109
-
H.
Chandler
(1985)
Data Base
Journal of Learning Disabilities, 18
-
(2012)
J Clin Oncol
-
G.
Oades,
J.
Coxon,
K.
Colston
(2002)
The potential role of bisphosphonates in prostate cancer
Prostate Cancer and Prostatic Diseases, 5
-
F.
Saad,
D.
Gleason,
R.
Murray,
S.
Tchekmedyian,
P.
Venner,
L.
Lacombe,
J.
Chin,
J.
Vinholes,
J.
Goas,
M.
Zheng
(2004)
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Journal of the National Cancer Institute, 96 11
-
David
Miller,
K.
Hafez,
A.
Stewart,
J.
Montie,
John
Wei
(2003)
Prostate carcinoma presentation, diagnosis, and staging
Cancer, 98
-
K.
Weinfurt,
Y.
Li,
Liana
Bruce,
F.
Saad,
J.
Timbie,
G.
Glendenning,
K.
Schulman
(2005)
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 16 4
-
M.
Rogers,
D.
Watts,
R.
Russell
(1997)
Overview of bisphosphonates
Cancer, 80
-
A.
Sartor,
D.
Fernandez,
M.
Morris,
A.
Iagaru,
Alan
Brown,
Fabio
Almeida,
C.
Sweeney,
M.
Smith,
A.
Dicker,
Y.
Wong,
N.
Shore,
Jeremy
Gratt,
O.
Petrenciuc,
J.
Germino,
N.
Vogelzang
(2015)
Ra-223 experience in pretreated patients: EAP setting.
Journal of Clinical Oncology, 33
-
M.
Smith,
J.
Bono,
Cora
Sternberg,
S.
Moulec,
S.
Oudard,
U.
Giorgi,
M.
Krainer,
A.
Bergman,
W.
Hoelzer,
R.
Wit,
M.
Boegemann,
F.
Saad,
G.
Cruciani,
A.
Vuillemin,
S.
Feyerabend,
K.
Miller,
D.
Ramies,
C.
Hessel,
A.
Weitzman,
K.
Fizazi
(2015)
Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
Journal of Clinical Oncology, 33
-
I.
Resche,
J.
Chatal,
A.
Pecking,
P.
Ell,
G.
Duchesne,
R.
Rubens,
I.
Fogelman,
S.
Houston,
A.
Fauser,
M.
Fischer,
D.
Wilkins
(1997)
A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.
European journal of cancer, 33 10
-
S.
Nilsson,
P.
Strang,
A.
Aksnes,
L.
Franzén,
P.
Olivier,
A.
Pecking,
J.
Staffurth,
S.
Vasanthan,
C.
Andersson,
Ø.
Bruland
(2012)
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.
European journal of cancer, 48 5
-
F.
Roghmann,
C.
Antczak,
R.
McKay,
T.
Choueiri,
Jim
Hu,
A.
Kibel,
Simon
Kim,
K.
Kowalczyk,
M.
Menon,
P.
Nguyen,
F.
Saad,
J.
Sammon,
M.
Schmid,
S.
Sukumar*,
M.
Sun,
J.
Noldus,
Q.
Trinh
(2015)
The burden of skeletal-related events in patients with prostate cancer and bone metastasis.
Urologic oncology, 33 1
-
E.
Silberstein,
C.
Williams
(1985)
Strontium-89 therapy for the pain of osseous metastases.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 26 4
-
F.
Saad,
N.
Shore,
H.
Poppel,
D.
Rathkopf,
Matthew
Smith,
J.
Bono,
C.
Logothetis,
P.
Souza,
K.
Fizazi,
P.
Mulders,
P.
Mainwaring,
J.
Hainsworth,
T.
Beer,
S.
North,
Y.
Fradet,
Thomas
Griffin,
P.
Porre,
A.
Londhe,
T.
Kheoh,
E.
Small,
H.
Scher,
A.
Molina,
C.
Ryan
(2015)
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
European urology, 68 4
-
P.
Hoskin,
O.
Sartor,
J.
O’Sullivan,
D.
Johannessen,
S.
Helle,
J.
Logue,
D.
Bottomley,
S.
Nilsson,
N.
Vogelzang,
F.
Fang,
M.
Wahba,
A.
Aksnes,
C.
Parker
(2014)
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
The Lancet. Oncology, 15 12
-
D.
Dearnaley,
M.
Sydes,
M.
Mason,
M.
Stott,
C.
Powell,
A.
Robinson,
P.
Thompson,
L.
Moffat,
S.
Naylor,
M.
Parmar
(2003)
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
Journal of the National Cancer Institute, 95 17
-
Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base.
-
L.
Costa,
X.
Badia,
E.
Chow,
A.
Lipton,
A.
Wardley
(2008)
Impact of skeletal complications on patients’ quality of life, mobility, and functional independence
Supportive Care in Cancer, 16
-
K.
Fizazi,
M.
Carducci,
Matthew
Smith,
R.
Damião,
Janet
Brown,
L.
Karsh,
P.
Milecki,
N.
Shore,
M.
Rader,
Huei
Wang,
Q.
Jiang,
Sylvia
Tadros,
R.
Dansey,
C.
Goessl
(2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
The Lancet, 377
-
Ann-Sofie
Fransson,
L.
Franzén,
S.
Gibbs,
J.
Graham,
A.
Haese*,
C.
Hampel,
R.
Harrup,
C.
Heath,
D.
Heinrich,
S.
Helle,
M.
Hora,
P.
Hoskin,
G.
Hudes,
M.
Jackson,
Nick
James,
B.
Jarzab,
P.
Jarzemski,
D.
Johannessen,
W.
Koff,
U.
Kasti,
C.
Keil,
J.
Kindblom,
O.
Klepp,
R.
Klijer,
J.
Kliment,
L.
Klotz,
I.
Kocák,
Andrzej
Kołodziejczyk,
M.
Kuczyk,
P.
Kwong,
M.
Lagerlund,
K.
Larsen,
A.
Leung,
Eugene
Leung,
R.
Llarena,
M.
Aglietta,
D.
Amadori,
E.
Aranda,
J.
Arbizu,
A.
Bahl,
V.
Baláž,
P.
Bello,
R.
Ben‐Yosef,
I.
Billiet,
D.
Bottomley,
J.
Breza,
Michael
Brown,
W.
Cabral,
Micheal
Cano,
J.
Carles,
P.
Chakraborti,
P.
Chłosta,
A.
Chodacki,
Robb
Coleman,
Marian
Cvik,
D.
Dalley,
M.
Dall'oglio,
R.
Damião,
M.
Goeij,
G.
Dickie,
S.
Dixit,
J.
Donas,
A.
Dowling,
Y.
Dror,
L.
Duck,
Monstserrat
Estorch,
U.
Falkmer,
D.
Feltl,
S.
Fosså,
J.
Logue,
Rafael
López,
Jarad
Martin,
G.
Marx,
B.
Mellado,
W.
Mermershtain,
C.
Messina,
J.
Michalski,
A.
Miller,
I.
Mincik,
J.
Money-Kyrle,
A.
Monnier,
André
Moraes,
A.
Murad,
C.
Ng,
C.
Nieder,
S.
Nilsson,
J.
O’Sullivan,
C.
Parker,
S.
Pascoe,
Samir
Patel,
A.
Pecking,
Jaroslav
Pernicka,
K.
Pittman
(2012)
Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 18_suppl
-
G.
Blake,
M.
Zivanovic,
A.
McEwan,
D.
Ackery
(1986)
Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate
European Journal of Nuclear Medicine, 12
-
J.
Araujo,
G.
Trudel,
F.
Saad,
A.
Armstrong,
E.
Yu,
J.
Bellmunt,
G.
Wilding,
J.
McCaffrey,
S.
Serrano,
V.
Matveev,
E.
Efstathiou,
S.
Oudard,
M.
Morris,
B.
Sizer,
P.
Goebell,
A.
Heidenreich,
J.
Bono,
S.
Begbie,
J.
Hong,
E.
Richardet,
E.
Gallardo,
P.
Paliwal,
S.
Durham,
Shinta
Cheng,
C.
Logothetis
(2013)
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
The Lancet. Oncology, 14 13
-
E.
Small,
Matthew
Smith,
J.
Seaman,
S.
Petrone,
M.
Kowalski
(2003)
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 23
-
Molecular pathways: targeted alpha-particle radiation therapy.
-
A.
Armstrong,
E.
Garrett-Mayer,
R.
Wit,
I.
Tannock,
M.
Eisenberger
(2009)
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 16
-
B.
Hellerstedt,
K.
Pienta
(2002)
The Current State of Hormonal Therapy for Prostate Cancer
CA: A Cancer Journal for Clinicians, 52
-
L.
Bubendorf,
Alain
Schöpfer,
U.
Wagner,
G.
Sauter,
H.
Moch,
N.
Willi,
Th.
Gasser,
M.
Mihatsch
(2000)
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.
Human pathology, 31 5
-
Julie
Brown,
Jian
Zhang,
E.
Keller
(2004)
Opg, RANKl, and RANK in cancer metastasis: expression and regulation.
Cancer treatment and research, 118
-
G.
Henriksen,
K.
Breistøl,
Ø.
Bruland,
Ø.
Fodstad,
R.
Larsen
(2002)
Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.
Cancer research, 62 11
-
J.
Aragon-Ching
(2009)
Further analysis of the survival benefit of clodronate
Cancer Biology & Therapy, 8
-
S.
Halabi,
N.
Vogelzang,
A.
Kornblith,
S.
Ou,
P.
Kantoff,
N.
Dawson,
E.
Small
(2008)
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 15
-
I.
Finlay,
M.
Mason,
M.
Shelley
(2005)
Radioisotopes for the palliation of metastatic bone cancer: a systematic review.
The Lancet. Oncology, 6 6
-
F.
Saad,
Janet
Brown,
C.
Poznak,
T.
Ibrahim,
S.
Stemmer,
A.
Stopeck,
I.
Diel,
Shunji
Takahashi,
N.
Shore,
D.
Henry,
C.
Barrios,
T.
Facon,
F.
Senecal,
K.
Fizazi,
Lei
Zhou,
A.
Daniels,
P.
Carrière,
R.
Dansey
(2012)
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
Annals of oncology : official journal of the European Society for Medical Oncology, 23 5
-
F.
Saad,
J.
Carles,
S.
Gillessen,
D.
Heinrich,
Jeremy
Gratt,
K.
Miller,
S.
Nilsson,
J.
O’Sullivan,
M.
Tucci,
M.
Wirth,
A.
Heidenreich
(2015)
Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRCP) patients
Onkologie, 38
-
S.
Nilsson,
R.
Larsen,
S.
Fosså,
L.
Balteskard,
K.
Borch,
J.
Westlin,
G.
Salberg,
Ø.
Bruland
(2005)
First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases
Clinical Cancer Research, 11
-
T.
Guise
(2000)
Molecular mechanisms of osteolytic bone metastases
Cancer, 88
-
A.
Stopeck,
K.
Fizazi,
J.
Body,
Janet
Brown,
M.
Carducci,
I.
Diel,
Y.
Fujiwara,
Miguel
Martín,
A.
Paterson,
K.
Tonkin,
N.
Shore,
P.
Sieber,
F.
Kueppers,
L.
Karsh,
D.
Yardley,
Huei
Wang,
T.
Maniar,
J.
Arellano,
A.
Braun
(2015)
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
Supportive Care in Cancer, 24
-
K.
Baidoo,
K.
Yong,
M.
Brechbiel
(2012)
Molecular Pathways: Targeted α-Particle Radiation Therapy
Clinical Cancer Research, 19
-
E.
Keller,
Julie
Brown
(2004)
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity
Journal of Cellular Biochemistry, 91
-
D.
Petrylak,
C.
Tangen,
M.
Hussain,
P.
Lara,
Jeffrey
Jones,
M.
Taplin,
P.
Burch,
D.
Berry,
C.
Moinpour,
M.
Kohli,
M.
Benson,
E.
Small,
D.
Raghavan,
E.
Crawford
(2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
The New England journal of medicine, 351 15
-
D.
Ernst,
I.
Tannock,
E.
Winquist,
P.
Venner,
L.
Reyno,
M.
Moore,
K.
Chi,
K.
Ding,
C.
Elliott,
W.
Parulekar
(2003)
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 17
-
(2015)
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
Annals of Oncology, 26